Former Genzyme Corporation Prez Joins $3.2 Million Round for Aura Biosciences
Published: Dec 28, 2012
Aura Biosciences, a Cambridge biotech that’s developing pseudo-viruses (PsV’s) for the treatment of cancer, announced it raised $3.2 million this summer from several investors, including Henri Termeer, former president of Genzyme. Termeer joined Aura as a corporate advisor, while the company also picked up two new directors: Jose Baselga, MD, physician-in-chief at Memorial-Sloan Kettering Cancer Center in New York, and Israel Ruiz, executive vice-president for finance at MIT. The $3.2 million was a second tranche of its Series A round, according to a statement from the company. The company’s last round was $4.5 million in August 2011, also a Series A round, which came from “a very small group of wealthy investors" who are all pharma entrepreneurs, said Elisabet de los Pinos, founder and CEO of Aura Biosciences, at that time. In total the company has raised more than $11 million since it was founded.